| Today's Top Story |  |  | |  | Fly a lot? Earn 3X rewards points on airline purchases with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  - Teva is developing compound for type 1 diabetes
Teva Pharmaceutical Industries plans to use the DiaPep277 compound to develop a treatment that would replace insulin therapy in some patients with type 1 diabetes. In a trial, the drug appeared to promote stable C-peptide levels, an indication of insulin secretion by pancreatic cells, researchers said. The results of a second late-stage trial are expected in 2014. Bloomberg (12/19)       - Metamark, Janssen partnership deal could exceed $365M
Janssen Biotech and Metamark Genetics have entered into a research, collaboration and licensing agreement centered on Metamark's Prognosis Determinants cancer drug discovery technology. Janssen will get limited exclusive licensing rights to certain drug targets discovered using Metamark's platform. If Janssen licenses multiple drug targets, Metamark could receive milestone payments of up to $365 million and royalties, in addition to initial upfront and short-term milestone fees. Mass High Tech (Boston) (12/19) - Advanced Cell Technology now at forefront of ESC research
Geron's decision to halt trials using embryonic stem cells to treat spinal cord injuries has placed Advanced Cell Technology at the forefront of embryonic stem cell research. "Obviously that puts a lot of pressure on us to deliver now," said Dr. Robert P. Lanza, Advanced Cell's chief scientific officer. The company is currently testing its stem cell treatments for Stargardt's macular dystrophy and dry age-related macular degeneration in clinical trials. Telegram & Gazette (Worcester, Mass.) (12/18) - Mutation may raise risk of secondary acute myeloid leukemia
A study showed that people with myelodysplastic syndrome and a missense mutation in the U2AF1 gene are at higher risk of developing secondary acute myeloid leukemia. This discovery, along with other research, "raises the possibility that mutations in splicing factors, including U2AF1, may be responsible for the observed alterations of splicing in cancer," researchers wrote online in the journal Nature Genetics. PhysiciansBriefing.com/HealthDay News (12/19) - Researchers create cells to restore blood vessels
Israeli researchers have created pericytes, cells needed to build blood vessels, through the reprogramming of embryonic stem cells. Mice with damaged blood vessels in the leg were able to generate new blood vessels after being injected with the newly developed pericytes, according to the study published in Circulation. The Jerusalem Post (free registration) (12/19)   | The Cutting Edge of Chemistry is a free report from Thomson Reuters, delivering an action-packed review of the latest synthesis schemes, scaffolds, mechanisms of action, and new structures shaping today's drug discovery and development pipeline. Extensively researched, this report gives you a deeper insight into the latest chemistry news that matters to you. Access the report here! |
 | Global Developments | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | | Industrial & Environmental | | | | | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Every great achievement is the victory of a flaming heart."
--Ralph Waldo Emerson,
American writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, December 19, 2011
- Friday, December 16, 2011
- Thursday, December 15, 2011
- Wednesday, December 14, 2011
- Tuesday, December 13, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment